11 Analysts Have This to Say About Akero Therapeutics
Portfolio Pulse from Benzinga Insights
11 Wall Street analysts have recently provided their opinions on Akero Therapeutics (NASDAQ:AKRO), with an average price target of $52.27, which is significantly higher than the current price of $13.95. The consensus among these analysts is positive, with 4 bullish and 7 somewhat bullish ratings. However, this target represents an 18.15% decrease from the previous target of $63.86. Analysts' ratings are based on comprehensive analysis, including company data and industry trends.
November 14, 2023 | 1:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Akero Therapeutics has received positive ratings from 11 analysts, with a current average price target of $52.27, which is much higher than its current price. This suggests a strong upside potential for the stock.
The unanimous positive outlook from analysts, combined with a significant price target above the current trading price, indicates strong confidence in the company's future performance. This could lead to increased investor interest and a potential rise in the stock price in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100